Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3

Απλή σελίδα τεκμηρίου
dc.contributor.authorAntoniou, K.en
dc.contributor.authorGalanopoulos, A.en
dc.contributor.authorVlachou, S.en
dc.contributor.authorKourouli, T.en
dc.contributor.authorNahmias, V.en
dc.contributor.authorThermos, K.en
dc.contributor.authorPanagis, G.en
dc.contributor.authorDaifoti, Z.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorPapahatjis, D.en
dc.contributor.authorSpyraki, C.en
dc.date.accessioned2015-11-24T19:33:19Z
dc.date.available2015-11-24T19:33:19Z
dc.identifier.issn0955-8810-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23524
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectBehavior, Animal/*drug effects/physiologyen
dc.subjectBinding, Competitive/drug effectsen
dc.subjectCannabinoids/chemistry/*pharmacologyen
dc.subjectCatalepsy/chemically induced/physiopathologyen
dc.subjectCell Membrane/drug effects/metabolismen
dc.subjectCerebral Cortex/drug effects/metabolismen
dc.subjectCyclohexanols/metabolismen
dc.subjectDose-Response Relationship, Drugen
dc.subjectMaleen
dc.subjectMolecular Structureen
dc.subjectMotor Activity/drug effectsen
dc.subjectPain/physiopathology/prevention & controlen
dc.subjectPain Measurement/methodsen
dc.subjectPiperidines/pharmacologyen
dc.subjectPyrazoles/pharmacologyen
dc.subjectRatsen
dc.subjectRats, Sprague-Dawleyen
dc.subjectReceptor, Cannabinoid, CB1/agonists/antagonists & inhibitors/physiologyen
dc.subjectTime Factorsen
dc.subjectTritiumen
dc.titleBehavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3en
heal.abstractNewly developed cannabinoids may hold the promise of the development of useful and safe drugs. This study aimed to investigate the behavioral effects of the novel 1',1'-dithiolane delta8-HC analogue AMG-3, a cannabinomimetic molecule with high affinity for CB1/CB2 receptors. This analog was chosen for its binding affinity to these receptors, which is higher than that reported for delta8-tetrahydrocannabinol (delta8-THC). Behavioral responses were assessed after the administration of AMG-3 (1, 2, 4, 8 mg/kg, i.p.) in the open field, on the bar test, on the hot plate and in the intracranial self-stimulation procedure. AMG-3 increased the reactivity time on the hot plate in a dose- and time-dependent manner, indicating a long-lasting analgesic effect (at least 24 h). The substance was found dose-dependently to decrease spontaneous motor activity and to induce catalepsy, particularly at the highest dose (8 mg/kg). AMG-3 did not affect the rewarding value of intracranial self-stimulation, except to increase the reward threshold at the highest dose (8 mg/kg). The effects of the highest dose of AMG-3 on spontaneous activity and on the self-stimulation paradigm were completely reversed by pre-treatment with the CB1 receptor antagonist AM-251. These findings indicate that the administration of AMG-3 to rats elicits a specific behavioral profile, most probably associated with the activation of CB1 receptors and without effects indicating abuse potential.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16148456-
heal.journalNameBehav Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ